Abstract
Purpose: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. Methods: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. Results: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. Conclusions: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
| Original language | English |
|---|---|
| Pages (from-to) | 427-434 |
| Number of pages | 8 |
| Journal | Sleep and Breathing |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jun 2012 |
Fingerprint
Keywords
- Groaning
- Parasomnia
- Side effect
- Sleep apnea
- Sleep-related breathing disorders
ASJC Scopus subject areas
- Otorhinolaryngology
- Clinical Neurology
Cite this
Catathrenia under sodium oxybate in narcolepsy with cataplexy. / Poli, Francesca; Ricotta, Lara; Vandi, Stefano; Franceschini, Christian; Pizza, Fabio; Palaia, Vincenzo; Moghadam, Keivan Kaveh; Banal, Donatella; Vetrugno, Roberto; Thorpy, Michael J.; Plazzi, Giuseppe.
In: Sleep and Breathing, Vol. 16, No. 2, 06.2012, p. 427-434.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Catathrenia under sodium oxybate in narcolepsy with cataplexy
AU - Poli, Francesca
AU - Ricotta, Lara
AU - Vandi, Stefano
AU - Franceschini, Christian
AU - Pizza, Fabio
AU - Palaia, Vincenzo
AU - Moghadam, Keivan Kaveh
AU - Banal, Donatella
AU - Vetrugno, Roberto
AU - Thorpy, Michael J.
AU - Plazzi, Giuseppe
PY - 2012/6
Y1 - 2012/6
N2 - Purpose: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. Methods: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. Results: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. Conclusions: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
AB - Purpose: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. Methods: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. Results: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. Conclusions: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
KW - Groaning
KW - Parasomnia
KW - Side effect
KW - Sleep apnea
KW - Sleep-related breathing disorders
UR - http://www.scopus.com/inward/record.url?scp=84860553541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860553541&partnerID=8YFLogxK
U2 - 10.1007/s11325-011-0520-2
DO - 10.1007/s11325-011-0520-2
M3 - Article
VL - 16
SP - 427
EP - 434
JO - Sleep and Breathing
JF - Sleep and Breathing
SN - 1520-9512
IS - 2
ER -